Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Novavax’s CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a recent ...
MIDDLETON, Wis.--(BUSINESS WIRE)--Imbed Biosciences (“Imbed”), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback